Strum Jay 4

4 · G1 Therapeutics, Inc. · Filed Jan 2, 2019

Form 4

Period: 2019-01-02

Chief Scientific Officer

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2019-01-02−13,333→ 0 total
Exercise: $0.39Exp: 2024-01-21→ Common Stock (13,333 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-01-02−27,000→ 0 total
Exercise: $0.39Exp: 2024-07-11→ Common Stock (27,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-01-02−15,816→ 0 total
Exercise: $0.30Exp: 2022-11-09→ Common Stock (15,816 underlying)
Exercise/Conversion
Common Stock
2019-01-02$0.30/sh+39,485$11,846→ 88,904 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-01-02−10,336→ 0 total
Exercise: $0.30Exp: 2023-01-09→ Common Stock (10,336 underlying)
Exercise/Conversion
Common Stock
2019-01-02$0.39/sh+40,333$15,730→ 129,237 total
Award
Stock Option (Right to Buy)
2019-01-02+15,000→ 15,000 total
Exercise: $19.56Exp: 2029-01-02→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-01-02−13,333→ 0 total
Exercise: $0.30Exp: 2023-04-16→ Common Stock (13,333 underlying)

Footnotes (2)

[F1]The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
[F2]All shares underlying this option have vested.

Documents

1 file